deutsch
english
francais
italiano
espanol
Photo
KEYCODE BAYER 508

October 21, 2011
Coalition against Bayer Dangers (Germany)

New Lifestyle Drug ATX-101

BAYER’s Anti-Fat Shot Rejected

Looking for new pharmaceutical markets, BAYER has now discovered ‘aesthetic medicine’ and is currently developing an injection for dissolving fat cells. Thus, the company intends to attack a scourge of humanity, the double chin, and is happy to risk side effects in the process.

Research pipelines must be very empty if a global player like the pharmaceutical producer BAYER concentrates on unnecessary projects. Over the last few months INTENDIS, a subsidiary of BAYER HEALTHCARE, and the Californian company KYTHERA BIOPHARMACEUTICALS, have been doing intense research to launch an injection that regionally dissolves fat.

This refers especially to fat beneath the chin, typically called a double chin. A substance called ATX-101 is expected to do away with the need for cosmetic surgery in this area and to dissolve the fat in the double chin instead.

INTENDIS claims that ATX-101 is a promising product, which the company intends to use to gain ground in the growing market for aesthetic medicine. As a reminder: this is the type of medical care that – apart from reconstructive surgery after accidents or operations, which is often useful – offers mainly liposuction, lip enhancements or breast and penis enlargements. It is a field affected by many problems, accidents and even deaths. An infamous incident in Germany was the ‘Cora case’: porn actress Carolin Wosnitza died at the age of 23 after complications during her sixth breast operation.

The medicinal forerunners to ATX-101 are the ingredients phophatidylcholine and deoxycholate (DC). Phosphatidylcholine (brand name: LIPOSTABIL) is known as a drug against overly high fat levels in the blood - a drug of dubitable efficiency. Its injection is supposed to prevent fat embolisms but is also used for fat removal. In spring 2010 the US American Food and Drug Administration (FDA) warned of the ‘lunch time lipo’, the quick liposuction during lunch break, since the use of phosphatidylcholine for this purpose had never been authorised. All the same the drug was used unscrupulously up to 2009, which was when doctors in France first noticed unwanted results: the fatty tissue got infected. Thereupon the use of the drug for this purpose was outlawed. However, the drug is still administered for this use ‘off label’ - without permission - in Germany.

In ATX-101 PC has now been replaced by DC, which is supposed to destroy the fat cells in small fat deposits such as the double chin. Since the human organism doesn’t grow new fat cells after puberty (apart from very rare exceptions), no new fat deposits can form in zones that have been treated that way. However, where does the dissolved fat go? Will the fat cells agglomerate and harden? How can it ever be made sure that such a drug isn’t also used in areas with large fat deposits, such as the abdomen? ‘Rambling’ fat could cause blockages of arteries and strokes. There might also be long-term damage to the treated areas of skin.

All the same, the researchers involved are eager to praise ATX-101 as a step forward in aesthetic medicine and the first injection for the minimally invasive removal of fat cells. Pharmaceutical research must be facing a severe crisis if a company like BAYER feels it needs to try its hand at aesthetic medicine. In any case, the ‘anti-fat shot’ is an item from the aesthetic junk shop of our time!
Prof. Gerd Glaeske (translation: Stephanie Laimer)

Docs Question Bayer's Injection for Dissolving Double Chin

A simple injection in the neck to get rid of that double chin? Sounds too good to be true, and that very well may be the case concerning Bayer's newest fat-dissolving injectable, ATX-101, which is beginning phase III trials in Europe.
The upcoming multi-center, randomized, double-blind, placebo-controled study will test the efficacy of ATX-101 for eliminating localized fat under the chin, known as submental fat. The companies announced Monday that they are enrolling patients for the trial in France, Germany, Belgium, Spain, Italy and the U.K.
The drug utilizes half of the two-drug, off-label cocktail used for the notoriously problematic fat-dissolving injectable Lipodissolve that prompted a public warning by the Food and Drug Administration in spring 2010.
Lipodissolve, which was marketed as a quick and easy "lunchtime lipo" procedure a few years back, utilized two chemicals, phosphatidylcholine (PC) and deoxycholate (DC), neither of which were FDA approved for fat elimination.
ATX-101, is just sodium deoxycholate (DC in solution).
Research has shown PC actually inhibits the fat-dissolving effects of DC, so researchers are testing the efficacy of DC alone for fat elimination, said KYTHERA Biopharmaceuticals, Inc., which teamed with Bayer in August 2010 for the upcoming trial.
KYTHERA hopes ultimately to bring an FDA-approved compound for injectable fat elimination to the U.S. market. Two phase II trials in humans have been done in the U.S. so far and a third is underway.
"We are very pleased with the progress that has been made in Europe with ATX-101," Keith Leonard, KYTHERA's president and CEO, said in a press release on the trial. "The initiation of these Phase III studies marks an important milestone in our collaboration with Intendis and further demonstrates the potential of ATX-101 as a first-in-class injectable drug for localized fat reduction."
But plastic surgeons are wary of this renewed attempt to test DC as a cosmetic fat-dissolver.
"I would be very cautious. Even if it's approved in Europe, people will start purchasing it and sneaking into the U.S. illegally," said Dr. Darrick Antell, a plastic surgeon at Roosevelt Hospital in New York and a spokesman for the American Society of Plastic Surgeons. "There's no doubt in my mind that if it's approved for the small area under the chin, then people will start using for large areas and I have no doubt that there will invariably be adverse effects. Injectable fat-dissolvers need a lot more work. People who would use this sort of medicine at this point would be like driving ahead of your headlights."

From Fatty Arteries to Fatty Thighs
The story of a fat-disolving injectable began with a drug called Lipostabil, approved for use in Germany, that was found to be effective at breaking down fatty buildup in the arteries known as atherosclerosis. When it was noted that Lipostabil may dissolve fat under the skin as well as in the arteries, people in the U.S. began approximating the drug (which was not approved in the U.S.) by combining its main ingredients, DC and PC and injecting it into fatty areas like the abdomen.
This combination, which became known as Lipodissolve, was not regulated, however, and the ingredients in any given injection were not standardized.
Because neither ingredient was approved by the FDA for fat elimination and the combination was not approved for anything in the U.S., use of Lipodissolve was a "double concern," said Dr. Malcolm Roth, director of plastic surgery at Maimondes Medical Center in Brooklyn, N.Y., and president-elect of the American Society of Plastic Surgeons.
"Infection, gangrene of the skin, scarring ,chronic pain and deformity are some of the adverse effects seen," said Roth.
"Some also experienced hard lumps where the fat cells had died and clumped together," added Antell.
Ultimately the FDA issued warnings to the public not to use Lipodissolve, and the combination was banned in Canada and Brazil.

Breaking Down Body Fat With Soap
It wasn't the combination that was dissolving fat however, noted Dr. Carolyn Jacob, director of Chicago Cosmetic Surgery and Dermatology, it was the DC alone.
Thus, with the trials of ATX-101, Bayer and KYTHERA are testing the safety and efficacy of using a DC solution, sodium deoxycholate, from controlled sources in hopes of producing an injectable that can get regulatory approval in the United States and abroad.

How would deoxycholate work?
Deoxycholate is a common ingredient in soap, that "you'd probably find in your laundry detergents," said Antell. "What soaps do in your laundry detergent is ... help dissipate fatty tissue so that you can get grease and oil stains out of your clothing."
The breakdown of fatty tissue is purportedly the same thing that's happening in the body when DC is injected subcutaneously.
"But you have to wonder: Where does that dissolved material go?" asked Antell.
Roth echoed the concerns, questioning whether small bits of fatty tissue could do damage to the liver, clog the arteries or potentially cause a stroke if they make their way to the brain through the blood stream.
Because there are existing means of breaking down fat using cooling that have not shown signs of adverse effect, Jacob said, "I'm less concerned about what happens to the dissolved fat as what happens when the medication seeps into the surrounding areas, possibly causing breakdown of the skin or other tissues."
This becomes a greater concern if DC is injected into large areas such as the abdomen and buttocks, despite the fact that it only currently is being tested for use in the small under-chin area.
Jacob, Antell and Roth said that if ATX-101 gets approved for ameliorating double chins, it undoubtedly would be used off-label for other larger, untested areas of the body.
"Any time there is an injection (for fat loss), there will be tremendous temptation for people to abuse it and possibly inject themselves," Antell said. "We all like minimally invasive surgeries, but it's still wait and see at this point (for ATX-101)]. I would be very cautious." By COURTNEY HUTCHISON, ABC News Medical Unit, Jan. 13, 2011